Profiel
Paul F.
Reid was the founder of ReceptoPharm, Inc. founded in 2001, where he held the title of Chief Executive Officer from 2009 to 2011.
He was also the Chief Executive Officer of Nutra Pharma Corp.
from 2008 to 2010 and held the title of Head-Scientific Affairs at Biotherapeutics, Inc. in 1993.
Dr. Reid obtained a doctorate degree from Imperial College London and an undergraduate degree from Trinity College Dublin in 1987.
Eerdere bekende functies van Paul F. Reid
| Bedrijven | Functie | Einde |
|---|---|---|
| NUTRA PHARMA CORP. | President | 18-11-2009 |
Biotherapeutics, Inc.
Biotherapeutics, Inc. BiotechnologyHealth Technology Operates as a pre-clinical stage company which develops small-molecule drugs to treat inflammation and type 2 diabetes | Corporate Officer/Principal | 01-01-1993 |
ReceptoPharm, Inc.
ReceptoPharm, Inc. Pharmaceuticals: MajorHealth Technology Develops proprietary therapeutic protein products | Algemeen Directeur | - |
Opleiding van Paul F. Reid
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 5 |
|---|---|
Nutra Pharma Corp.
Nutra Pharma Corp. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products for treat pain, autoimmune disorders, viral diseases | Health Technology |
Imperial College London
Imperial College London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
ReceptoPharm, Inc.
ReceptoPharm, Inc. Pharmaceuticals: MajorHealth Technology Develops proprietary therapeutic protein products | Health Technology |
Trinity College Dublin
Trinity College Dublin Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Biotherapeutics, Inc.
Biotherapeutics, Inc. BiotechnologyHealth Technology Operates as a pre-clinical stage company which develops small-molecule drugs to treat inflammation and type 2 diabetes | Health Technology |
















